Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Wins Post-Operative Indication For Antiemetic Aloxi

This article was originally published in The Pink Sheet Daily

Executive Summary

Gained through the acquisition of MGI Pharma, drug adds indication for post-operative nausea and vomiting.
Advertisement

Related Content

Eisai’s Oral Aloxi Approved For Chemo-related Nausea/Vomiting
Eisai’s Oral Aloxi Approved For Chemo-related Nausea/Vomiting
Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition
Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition
MGI/Helsinn’s Aloxi Adds Multi-Day Dosing To Label

Topics

Advertisement
UsernamePublicRestriction

Register

PS067497

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel